ONC: Access to personal health information getting easier, barriers remain

locked-up device - 51.40 Kb
An informed patient is a healthy patient. Having access to personal health information (PHI) helps patients manage their health better, make informed decisions, improve their likelihood of positive outcomes and contributes to lowering system-wide healthcare costs. Despite the benefits and the capability in the form of personal health records (PHRs), barriers still prevent access to PHI, according to a June 3 policy brief from the Office of the National Coordinator for Health IT (ONC).

“Many individuals are unaware of their legal right to ask for a copy of their health information from their providers,” wrote the brief’s author, Jamie Skipper, RN, PhD. “There are also cultural and operational challenges that may prevent individuals from asking for and receiving a copy of their records, such as limited time during office visits, an unwillingness to be viewed as challenging their doctor, or non-standardized provider processes to support the individual’s request for a copy of her records.”

While HIPPA, the HITECH Act, EHR incentive programs and other initiatives have somewhat alleviated the barriers to receiving PHI, others remain. Patient identification, privacy concerns with PHRs and incompatibility between PHRs and EHRs make delivering sensitive information to the right person difficult for providers.

“The ONC has been working with federal, state and private partners to leverage current legislation and regulations to design health IT policies and programs that enhance individuals’ electronic access to their information in a timely manner,” Skipper wrote.

The complete policy brief is available here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.